Schulz R, Antonin K H, Hoffmann E, Jedrychowski M, Nilsson E, Schick C, Bieck P R
Human Pharmacology Institute, Ciba-Geigy GmbH, Tübingen, West Germany.
Clin Pharmacol Ther. 1989 Nov;46(5):528-36. doi: 10.1038/clpt.1989.181.
The effect of the monoamine oxidase inhibitor selegiline on tyramine metabolism and intravenous and oral tyramine pressor sensitivity was studied in healthy subjects. After oral doses of tyramine, which caused systolic blood pressure to increase by 30 mm Hg, we determined plasma concentrations of p-hydroxyphenylacetic acid (HPAA) and of conjugated and unconjugated tyramine. When 20 mg/day of selegiline was administered, the AUCspec of HPAA decreased from 86% to 64% and the AUCspec of conjugated tyramine increased from 13% to 35% of the sum of total tyramine and HPAA. Pressor sensitivity was enhanced more with oral administration of tyramine than with intravenous administration of tyramine. After the drug was discontinued, initial values were reached within 4 days (one subject) and 2 weeks (two subjects). Fifty-five percent of the selegiline dose was eliminated in urine as amphetamine and methamphetamine. The findings support the assumption that selegiline does not selectively inhibit monoamine oxidase-B (MAO-B) when administered in doses of 20 mg/day and higher.
在健康受试者中研究了单胺氧化酶抑制剂司来吉兰对酪胺代谢以及静脉注射和口服酪胺升压敏感性的影响。口服酪胺使收缩压升高30 mmHg后,我们测定了对羟基苯乙酸(HPAA)以及结合型和非结合型酪胺的血浆浓度。当给予司来吉兰20 mg/天时,HPAA的特异性曲线下面积(AUCspec)从86%降至64%,结合型酪胺的AUCspec从酪胺和HPAA总和的13%增至35%。口服酪胺比静脉注射酪胺时升压敏感性增强更明显。停药后,1名受试者在4天内、2名受试者在2周内恢复到初始值。司来吉兰剂量的55%以苯丙胺和甲基苯丙胺形式经尿液排出。这些发现支持了以下假设:当司来吉兰以20 mg/天及更高剂量给药时,它不会选择性抑制单胺氧化酶-B(MAO-B)。